|
| Webinar: Improving the discovery of novel drugs with artificial intelligence Thursday, February 3, 2022 | 2pm ET / 11am PT This webinar will cover the newest and most innovative AI solutions that have been developed for the life sciences industry. Topics include how AI can be used to improve the ability to predict which compounds are likely to make it to late-stage trials, best practices for choosing and partnering with technology developers to maximize the benefits of AI in drug development, and more. Register now. |
Pfizer's megablockbuster-to-be COVID pill Paxlovid scores FDA nod 2022 forecast: We wish we had better news for biotech dealmaking, but omicron is coming anyway 2022 forecast: Will biopharma's offices ever go back to 'normal'? Sanofi, Novartis and more chime in 2022 forecast: AR, VR poised to send medtech into the next dimension Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators 2022 forecast: Competition in retail healthcare will heat up. Here's what to expect from Amazon, CVS and Walgreens 2022 forecast: Cell, gene therapy makers push past regulatory, payer hurdles to set up high hopes for next year 2022 forecast: Talent war in life sciences, salary inflation in C-suite builds to 'negative feedback loop' Microsoft’s $19.7B Nuance purchase secures EU sign-off after antitrust investigation 2022 forecast: 5 trends that will make or break healthcare's labor shortages Novartis inks $800M upfront buyout of Gyroscope to continue eye disease gene therapy M&A spree Verily COO tacks on president title as CEO steps back from day-to-day duties 2022 forecast: Blood test breakthroughs set to move the needle in Alzheimer's, Parkinson's research 13.6M have signed up for coverage on ACA exchanges during open enrollment so far: CMS Featured Story | By Kevin Dunleavy The FDA sanctioned Pfizer’s Paxlovid for emergency use. The drug is a highly anticipated oral medicine for recently infected individuals who are at a high risk of progressing to a severe form of the disease. For Pfizer, the authorization will bring another massive pandemic windfall. read more |
| |
|---|
|
Top Stories By Annalee Armstrong We thought we’d finally get to see what a post-pandemic world looked like in 2022, but thanks to omicron, it seems we’re in for another round of virtual dealmaking and more. read more By Eric Sagonowsky Through much of 2021, it seemed as if COVID-19 vaccines were enabling many countries to gently ease back into normalcy. Those hopes hit a rude awakening late in the year when the omicron variant emerged, and now industry leaders are forced—again—to quickly adapt. read more By Andrea Park A recent market research report estimated that between 2021 and 2026, the market for virtual reality in healthcare will grow by nearly 35% annually, swelling the market to more than $40 billion. read more By Angus Liu Biogen and Eisai’s attempt to expand controversial Alzheimer’s disease drug Aduhelm has hit a snag in another large market. read more By Rebecca Torrence Walmart, CVS, Walgreens and Amazon have placed huge bets on healthcare this year. In 2022, industry experts anticipate that retailers will ramp up their investments in key technologies and tackle issues like social determinants of health and data sharing. read more By Arlene Weintraub Novartis, Bristol Myers Squibb and Gilead are among the companies expected to bring in high revenues from their cell and gene therapies in 2022. And the late-stage pipeline could produce several more cancer CAR-Ts and gene therapies to treat a range of diseases. read more By Kyle LaHucik Biopharmas are not immune to the "Great Resignation" spurred by the pandemic, and drug developers will have to create new formulations to attract and retain talent, or at least improve current hiring practices, to stave off mass quitting in 2022. read more By Andrea Park One antitrust probe down, one more to go for Microsoft and its $19.7 billion bid to buy Nuance Communications. read more By Dave Muoio Analysts and stakeholders highlight five industry trends that will make or break healthcare’s labor shortage in the months and years to come. read more By Nick Paul Taylor Gyroscope Therapeutics has been spun this way and that in 2021, going from a $148 million raise to a failed IPO to a $40 million investment from Sanofi in quick succession. But Novartis has ensured the gene therapy startup has ended the year at the top of its arc by inking a $1.5 billion buyout. read more By Andrea Park Stephen Gillett’s annual evaluation must have gone well: After just one year as chief operating officer at Verily, he’s been promoted to take on the role of president, too. read more By Conor Hale As is the case with nearly any biomedical endeavor, the inability to easily peek into the body’s inner workings severely stymies research. While progress has been made in cancer and other diseases, the brain has proven to be a tough nut to crack. That may be changing soon, with the advent of new blood diagnostics. read more By Paige Minemyer A record 13.6 million people have signed up for coverage on the Affordable Care Act's exchanges, according to new data from CMS. read more |
| Webinar: A Collaborative Approach to Complex Chemistry Wednesday, January 12, 2022 | 11am ET / 8am PT Complex therapeutics demand complex chemistry expertise. Discover how the right partner can help you overcome complex chemistry challenges through extensive experience, specialised technologies, and true scientific collaboration. Register now. |
|
